

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

27777

7590

10/18/2007

PHILIP S. JOHNSON
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003



Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

<i>JESUS JOAQUIN TIMONEDA</i>	(Depositor's name)
<i>[Signature]</i>	(Signature)
NOVEMBER 1, 2007	
(Date)	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/075,673

02/13/2002

J. Guy Breitenbacher

ORT-1590

2680

TITLE OF INVENTION: METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	01/18/2008
EXAMINER		ART UNIT	CLASS-SUBCLASS	11/01/2007 MGEBREM2 000000066 10075673 10075673		
WANG, SHENGJUN		1617	514-252130	81 FC:1501	1440.00 DA	
				82 FC:1504	300.00 DA	

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
 Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list
(1) the names of up to 3 registered patent attorneys or agents OR, alternatively, _____
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

JANSSEN PHARMACEUTICA, N.V.

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

BEERSE, BELGIUM

Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government

4a. The following fee(s) are submitted:

Issue Fee
 Publication Fee (No small entity discount permitted)
 Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

A check is enclosed.
 Payment by credit card. Form PTO-2038 is attached.
 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number *10-0750* (enclose an extra copy of this form).

5. Change in Entity Status (from stamp indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature: *[Signature]*

Date *November 1, 2007*

Typed or printed name *JESUS JOAQUIN TIMONEDA*

Registration No. *43332*

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Johnson & Johnson

Pharmaceutical Research & Development, L.L.C.
3210 Merryfield Row
San Diego, California 92121-1126
Phone: (858) 320-3549
Fax: (858) 784-3044

FACSIMILE TRANSMISSION SHEET

Date: November 1, 2007
To: ISSUE FEE DEPARTMENT
USPTO

Fax No.: (571) 273-2885
From: Jesus Joanos I Timoneda, Reg. No. 43,332

Total Pages (including this page): **3**

Re: U.S. Non-Provisional Application No. 10/075,673 filed February 13, 2002
Title: METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES
Atty Docket: ORT-1590

Attached please find the Form PTOL-85 Fee Transmittal Part B and Issue Fee payment (in duplicate) for the above referenced application.


In the event that any additional fees are required for the filing of this application, please charge such fees to Deposit Account No, 10-0750.

Should you have any question, please contact us at (858) 320-3549.

CONFIDENTIALITY NOTICE: This facsimile transmission, including this cover sheet and any documents that may accompany it, contains information from Johnson & Johnson intended only for the use of the individual or entity to which it is addressed, which may contain information that is privileged, confidential, and/or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, any disclosure, dissemination, distribution, copying or other use of this communication or its substance is prohibited. If you have received this communication in error, please call us "collect" to arrange for the destruction of the communication or its return to us at our expense. Thank you.

Certificate of transmission:

The undersigned certifies that the accompanying 2 pages are being facsimile transmitted to the USPTO (571) 273-2885 on the date indicated below.


Jesus Joanos I Timoneda (Reg. No. 43,332)
November 1, 2007